Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Global Cell Therapy Market Report 2017-2021: Proliferation of Strategic Alliances and Royalty Payments

Research and Markets
Posted on: 03 Oct 17
Global Cell Therapy Market Report 2017-2021: Proliferation of Strategic Alliances and Royalty Payments

PR Newswire

DUBLIN, October 3, 2017

DUBLIN, October 3, 2017 /PRNewswire/ --

The "Global Cell Therapy Market 2017-2021" report has been added to Research and Markets' offering.

The global cell therapy market to grow at a CAGR of 23.27% during the period 2017-2021.

Global Cell Therapy Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Cell therapy products, which are derived from stem cells, tissues, and organs grown in laboratories, are injected into patients. The growing number of clinical trials, government and private funding, and increasing number of partnerships between companies are driving the growth of the global cell therapy market. Cell therapy products that are available in the market are based on autologous and allogenic cells. The demand of cell therapy treatment is increasing. This is because cell therapy products can be used for personalized treatment.

The latest trend gaining momentum in the market is Proliferation of strategic alliances and royalty payments. Strategic alliances have affected the growth of the market in emerging regions such as APAC. Several vendors prefer M&A to strengthen their global position and improve their commercial capabilities. Through strategic alliances, many companies are receiving upfront and royalty payments, which they use for R&D to develop novel regenerative medicine products.

According to the report, one of the major drivers for this market is Increase in prevalence of chronic diseases. The prevalence of chronic diseases such as diabetes and CVDs is growing. Diabetes causes diabetic retinopathy and diabetic foot ulcer. CVDs such as coronary heart disease (CHD) can cause stroke. The increase in prevalence of chronic diseases increases the cost burden on healthcare systems. For instance, according to the CDC, in February 2010, stroke and heart disease cost the Government of the US around $315.4 billion. Cell therapy products can treat such diseases and reduce the economic burden on healthcare systems.

Further, the report states that one of the major factors hindering the growth of this market is High cost of clinical trials and cell therapy doses. The cost of clinical trials and product launches can increase the cost burden on manufacturers. Most companies that offer cell therapy products are small. Such companies require government or private funding. However, most organizations provide limited funding only if the target goal is achieved.

Key vendors

  • Dendreon
  • Mesoblast
  • Vericel

Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

  • Overview
  • Government funding and support

PART 05: Market landscape

  • Overview
  • Market size and forecast
  • PART 06: Pipeline portfolio
  • Overview
  • Regulatory framework for cell therapy products
  • Pipeline analysis
  • Five forces analysis

PART 07: Segmentation by application

  • Overview
  • Dermatology
  • Musculoskeletal
  • Ocular
  • Cardiovascular

PART 08: Segmentation by end-user

  • Hospitals and clinics
  • ASCs
  • Regenerative medicine centers

PART 09: Segmentation by geography

  • Overview
  • Americas
  • EMEA
  • APAC

PART 10: Decision framework

PART 11: Drivers and challenges

  • Market drivers
  • Market challenges

PART 12: Market trends

  • Focus on business strategies
  • Proliferation of strategic alliances and royalty payments
  • Geographic expansion of gene therapy

PART 13: Vendor landscape

  • Competitive landscape

PART 14: Key vendor analysis

  • Dendreon
  • Mesoblast
  • Vericel
  • Other prominent vendors

PART 15: Appendix

For more information about this report visit

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:

SOURCE Research and Markets

PR Newswire

Last updated on: 03/10/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.